{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:52:55Z","timestamp":1760575975538,"version":"build-2065373602"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clon.2004.11.010","type":"journal-article","created":{"date-parts":[[2005,3,16]],"date-time":"2005-03-16T07:14:06Z","timestamp":1110957246000},"page":"174-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["What's new in the management of cutaneous T-cell lymphoma?"],"prefix":"10.1016","volume":"17","author":[{"given":"V.","family":"McFarlane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.S.","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.M.","family":"Illidge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2004.11.010_bib1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jama.1988.03410010050033","article-title":"Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology","volume":"260","author":"Weinstock","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.clon.2004.11.010_bib2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/jnci\/81.20.1560","article-title":"Mycosis fungoides in relation to environmental exposures and immune response: a case\u2013control study","volume":"81","author":"Whittemore","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2004.11.010_bib3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/archderm.1987.01660260066015","article-title":"A case\u2013control study of possible causative factors in mycosis fungoides","volume":"123","author":"Tuyp","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib4","first-page":"160","article-title":"The role of human T-cell lymphotropic viruses (HTLV-I and II) in cutaneous T-cell lymphomas","volume":"13","author":"Zucker-Franklin","year":"1994","journal-title":"Semin Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib5","first-page":"667","article-title":"No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma","volume":"150","author":"Wood","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clon.2004.11.010_bib6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(05)64569-2","article-title":"HHV-8 in lymphoproliferative lesions in skin","volume":"348","author":"Sander","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2004.11.010_bib7","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0140-6736(04)70095-1","article-title":"Lack of evidence of HHV-8 in mature T-cell lymphoproliferative disorders","volume":"348","author":"Pawson","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2004.11.010_bib8","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V89.1.32.32_32_40","article-title":"Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion","volume":"89","author":"Jackow","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib9","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-07-2247","article-title":"Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome","volume":"101","author":"Herne","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib10","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1172\/JCI115920","article-title":"Interleukin-7 is a growth factor for Sezary lymphoma cells","volume":"90","author":"Dalloul","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clon.2004.11.010_bib11","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood.V89.9.3371","article-title":"Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides\/Sezary syndrome","volume":"89","author":"Thangavelu","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib12","first-page":"413","article-title":"Description des maladies de la peau observees a l'Hopital St Louis, Paris, France","author":"Alibert","year":"1806","journal-title":"Barrois L'aine et Fils"},{"key":"10.1016\/j.clon.2004.11.010_bib13","unstructured":"Bazin PAE. Maladies de la peau Observees a l'Hopital St Louis, Paris, France, 1876."},{"key":"10.1016\/j.clon.2004.11.010_bib14","first-page":"354","article-title":"EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer","volume":"90","author":"Willemze","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib15","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1200\/JCO.2000.18.15.2908","article-title":"Primary cutaneous T-cell lymphoma: review and current concepts","volume":"18","author":"Siegel","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib16","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1365-2133.2003.05698.x","article-title":"Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas","volume":"149","author":"Whittaker","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib17","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous T-Cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clon.2004.11.010_bib18","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/1097-0142(19900501)65:9<2069::AID-CNCR2820650930>3.0.CO;2-D","article-title":"Epidermal Langerhans' cell densities influence survival in mycosis fungoides and Sezary syndrome","volume":"65","author":"Meissner","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2004.11.010_bib19","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/0190-9622(95)90067-5","article-title":"CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides","volume":"32","author":"Hoppe","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1067\/mjd.2001.117722","article-title":"A modified staging classification for cutaneous T-cell lymphoma","volume":"45","author":"Kashani-Sabet","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1200\/JCO.2001.19.3.779","article-title":"Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides","volume":"19","author":"de Coninck","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib24","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1987.5.2.208","article-title":"Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis","volume":"5","author":"Dmitrovsky","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib25","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2004.11.010_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib27","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechlorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib29","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J Am Acad Dermatol"},{"issue":"5 Pt 1","key":"10.1016\/j.clon.2004.11.010_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib31","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib32","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.1992.01680170063007","article-title":"Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.clon.2004.11.010_bib33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"issue":"suppl 6","key":"10.1016\/j.clon.2004.11.010_bib34","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib36","first-page":"536","article-title":"Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group","volume":"69","author":"Thomsen","year":"1989","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clon.2004.11.010_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0360-3016(97)00553-1","article-title":"Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides)","volume":"40","author":"Wilson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2004.11.010_bib38","first-page":"691","article-title":"Electron-beam therapy for mycosis fungoides: the Stanford University experience","volume":"63","author":"Hoppe","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.clon.2004.11.010_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000421-199204000-00005","article-title":"Total skin electron beam radiation therapy for mycosis fungoides","volume":"15","author":"Reddy","year":"1992","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib40","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2004.11.010_bib41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0167-8140(99)00162-0","article-title":"Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation","volume":"54","author":"Maingon","year":"2000","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S1473-0502(02)00103-9","article-title":"Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma","volume":"28","author":"Knobler","year":"2003","journal-title":"Transfus Apheresis Sci"},{"key":"10.1016\/j.clon.2004.11.010_bib43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clon.2004.11.010_bib44","first-page":"1","article-title":"Photopheresis update","volume":"25","author":"Edelson","year":"1991","journal-title":"Prog Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib45","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0190-9622(96)90118-8","article-title":"Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy","volume":"35","author":"Zic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib46","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0190-9622(92)70212-X","article-title":"Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy","volume":"27","author":"Heald","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib47","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/archderm.1991.01680090099012","article-title":"Combined therapy for Sezary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations","volume":"127","author":"Rook","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib48","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib49","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/archderm.1993.01680300143034","article-title":"The sign of Leser-Trelat in association with Sezary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa","volume":"129","author":"Cohen","year":"1993","journal-title":"Arch Dermatol"},{"issue":"Pt 1","key":"10.1016\/j.clon.2004.11.010_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0190-9622(99)70137-4","article-title":"Role of extracorporeal photochemotherapy alone and in combination with interferon alfa in the treatment of cutaneous T-cell lymphoma","volume":"41","author":"Fimiani","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00000421-199406000-00016","article-title":"Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response","volume":"17","author":"Vonderheid","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib52","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clon.2004.11.010_bib53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0140-6736(05)66242-3","article-title":"Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma","volume":"350","author":"Dippel","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2004.11.010_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1046\/j.1365-2133.1999.02704.x","article-title":"Long-term follow-up in 51 patients with mycosis fungoides and Sezary syndrome treated by interferon-alfa","volume":"140","author":"Jumbou","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1 Pt 1","key":"10.1016\/j.clon.2004.11.010_bib56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1067\/mjd.2000.105510","article-title":"Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides","volume":"43","author":"Wilson","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"4 Pt 1","key":"10.1016\/j.clon.2004.11.010_bib57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0190-9622(89)70251-6","article-title":"Low-dose methotrexate for the Sezary syndrome","volume":"21","author":"Zackheim","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clon.2004.11.010_bib59","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1182\/blood.V61.2.279.279","article-title":"An investigation of 2\u2032-deoxycoformycin in the treatment of cutaneous T-cell lymphoma","volume":"61","author":"Grever","year":"1983","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J Clin Oncol"},{"issue":"Pt 1","key":"10.1016\/j.clon.2004.11.010_bib62","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2\u2032-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib63","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0190-9622(88)70224-8","article-title":"Treatment of cutaneous T cell lymphoma with 2\u2032-deoxycoformycin (pentostatin)","volume":"19","author":"Dang-Vu","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib64","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00432-002-0403-9","article-title":"Liposomal daunorubicin in tumor stage cutaneous T-cell lymphoma: report of three cases","volume":"129","author":"Wollina","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib66","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl","key":"10.1016\/j.clon.2004.11.010_bib67","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/1097-0142(19860415)57:8+<1689::AID-CNCR2820571311>3.0.CO;2-M","article-title":"The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas","volume":"57","author":"Bunn","year":"1986","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2004.11.010_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib69","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib70","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.1994.12.10.2051","article-title":"Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"12","author":"Foss","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib71","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib72","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.2001.tb03721.x","article-title":"The role for interleukin-12 therapy of cutaneous T cell lymphoma","volume":"941","author":"Rook","year":"2001","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clon.2004.11.010_bib73","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/jnci\/82.3.208","article-title":"Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma","volume":"82","author":"Kaplan","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clon.2004.11.010_bib74","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(83)92136-0","article-title":"Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid","volume":"1","author":"Kessler","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.clon.2004.11.010_bib75","series-title":"Retinoids: new trends in research and therapy","first-page":"341","article-title":"13-cis-retinoic acid in mycosis fungoides","author":"Molin","year":"1985"},{"key":"10.1016\/j.clon.2004.11.010_bib76","first-page":"273","article-title":"Cutaneous T-cell lymphoma","author":"Foss","year":"2002","journal-title":"Haematology (Am Soc Haematol Educ Prog)"},{"key":"10.1016\/j.clon.2004.11.010_bib77","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clon.2004.11.010_bib78","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0959-8049(96)00327-9","article-title":"Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies","volume":"33","author":"Nichols","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clon.2004.11.010_bib79","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clon.2004.11.010_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","article-title":"Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides","volume":"39","author":"Saleh","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib81","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3816\/CLM.2001.n.005","article-title":"Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication","volume":"1","author":"Foss","year":"2001","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.clon.2004.11.010_bib82","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood.V87.3.893.bloodjournal873893","article-title":"Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody","volume":"87","author":"Knox","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib83","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib84","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1046\/j.1365-2230.2002.01147.x","article-title":"Vaccination therapy for cutaneous T-cell lymphoma","volume":"27","author":"Muche","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.clon.2004.11.010_bib85","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clon.2004.11.010_bib86","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655505000087?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655505000087?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:24:43Z","timestamp":1760541883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655505000087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S0936655505000087"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2004.11.010","relation":{},"ISSN":["0936-6555"],"issn-type":[{"type":"print","value":"0936-6555"}],"subject":[],"published":{"date-parts":[[2005,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What's new in the management of cutaneous T-cell lymphoma?","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2004.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}